Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

BACKGROUND: Graft-versus-Host Disease (GvHD) causes significant morbidity and mortality in patients after allogeneic stem cell transplantation. Donor T-cells cause inflammation and tissue damage in GvHD target organs such as liver, gut and skin. Cytokine receptor associated kinases JAK1 and JAK2 are...

Descripción completa

Detalles Bibliográficos
Autores principales: von Bubnoff, Nikolas, Ihorst, Gabriele, Grishina, Olga, Röthling, Nadine, Bertz, Hartmut, Duyster, Justus, Finke, Jürgen, Zeiser, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245867/
https://www.ncbi.nlm.nih.gov/pubmed/30453910
http://dx.doi.org/10.1186/s12885-018-5045-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245867/
https://www.ncbi.nlm.nih.gov/pubmed/30453910
http://dx.doi.org/10.1186/s12885-018-5045-7

Ejemplares similares